Saracatinib difumarate (BioDeep_00000839948)
代谢物信息卡片
Saracatinib difumarate
化学式: C35H40ClN5O13 (773.2311020000001)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O
InChI: 2*2-1+
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D000970 - Antineoplastic Agents
D004791 - Enzyme Inhibitors
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Shaunik Sharma, Steven Carlson, Adriana Gregory-Flores, Andy Hinojo-Perez, Ashley Olson, Thimmasettappa Thippeswamy. Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy.
Neurobiology of disease.
2021 08; 156(?):105410. doi:
10.1016/j.nbd.2021.105410. [PMID: 34087381] - Saad Tayyab, Milisha Koh A Magesvaran, Md Zahirul Kabir, Nor Farrah Wahidah Ridzwan, Saharuddin B Mohamad. Biophysical and computational view on the in vitro combination between an anticancer drug, saracatinib and human serum albumin.
Journal of biomolecular structure & dynamics.
2021 Jul; 39(10):3565-3575. doi:
10.1080/07391102.2020.1766571. [PMID: 32397949] - Peter E Hall, Scott T C Shepherd, Janet Brown, James Larkin, Robert Jones, Christy Ralph, Robert Hawkins, Simon Chowdhury, Ekaterini Boleti, Amit Bahl, Kate Fife, Andrew Webb, Simon J Crabb, Thomas Geldart, Robert Hill, Joanna Dunlop, Duncan McLaren, Charlotte Ackerman, Akhila Wimalasingham, Luis Beltran, Paul Nathan, Thomas Powles. Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
European urology focus.
2020 09; 6(5):999-1005. doi:
10.1016/j.euf.2019.01.010. [PMID: 30738795] - Xia Bian, Siwei Wu, Xiaoxue Yin, Liangliang Mu, Fangfang Yan, Linghe Kong, Zheng Guo, Liting Wu, Jianmin Ye. Lyn is involved in host defense against S. agalactiae infection and BCR signaling in Nile tilapia (Oreochromis niloticus).
Developmental and comparative immunology.
2019 07; 96(?):1-8. doi:
10.1016/j.dci.2019.02.013. [PMID: 30822451] - Anne Buffière, Théo Accogli, Laetitia Saint-Paul, Géraldine Lucchi, Benjamin Uzan, Paola Ballerini, Jean-Noël Bastie, Laurent Delva, Françoise Pflumio, Ronan Quéré. Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.
Leukemia.
2018 09; 32(9):2062-2065. doi:
10.1038/s41375-018-0081-5. [PMID: 29535432] - Yuzhen Zhou, Li Chu, Qi Wang, Weixing Dai, Xiaozhou Zhang, Jianfeng Chen, Ling Li, Peipei Ding, Long Zhang, Hongyu Gu, Luying Li, Xinyue Lv, Wei Zhang, Danlei Zhou, Pingzhao Zhang, Guoxiang Cai, Kuaile Zhao, Weiguo Hu. CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair.
Cell death & disease.
2018 08; 9(9):887. doi:
10.1038/s41419-018-0895-0. [PMID: 30166523] - Shaunik Sharma, Steven Carlson, Sreekanth Puttachary, Souvarish Sarkar, Lucas Showman, Marson Putra, Anumantha G Kanthasamy, Thimmasettappa Thippeswamy. Role of the Fyn-PKCδ signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy.
Neurobiology of disease.
2018 02; 110(?):102-121. doi:
10.1016/j.nbd.2017.11.008. [PMID: 29197620] - Jiaming Chen, Ying Peng, Jiang Zheng. Cytochrome P450 Mediated Bioactivation of Saracatinib.
Chemical research in toxicology.
2016 11; 29(11):1835-1842. doi:
10.1021/acs.chemrestox.6b00242. [PMID: 27769111] - Seon Min Woo, Kyoung-Jin Min, In Gyeong Chae, Kyung-Soo Chun, Taeg Kyu Kwon. Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways.
Molecular carcinogenesis.
2015 Mar; 54(3):216-28. doi:
10.1002/mc.22092. [PMID: 24127286] - Thera C Lewis, Ron Prywes. Serum regulation of Id1 expression by a BMP pathway and BMP responsive element.
Biochimica et biophysica acta.
2013 Oct; 1829(10):1147-59. doi:
10.1016/j.bbagrm.2013.08.002. [PMID: 23948603] - Yasuhito Fujisaka, Yusuke Onozawa, Takayasu Kurata, Hirofumi Yasui, Isao Goto, Kentaro Yamazaki, Nozomu Machida, Junichiro Watanabe, Hitoshi Shimada, Xiaojin Shi, Narikazu Boku. First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
Investigational new drugs.
2013 Feb; 31(1):108-14. doi:
10.1007/s10637-012-9809-7. [PMID: 22415795] - Lanfang Bai, Joy C Yang, Joon-ha Ok, Philip C Mack, Hsing-Jien Kung, Christopher P Evans. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
International journal of cancer.
2012 Jun; 130(11):2693-702. doi:
10.1002/ijc.26303. [PMID: 21792888] - Rosemary A Hannon, Richard D Finkelman, Glen Clack, Renee B Iacona, Martin Rimmer, Fatma Gossiel, José Baselga, Richard Eastell. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Bone.
2012 Apr; 50(4):885-92. doi:
10.1016/j.bone.2011.12.017. [PMID: 22245630] - Weng Ieong Tou, Calvin Yu-Chian Chen. In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
PloS one.
2012; 7(3):e33728. doi:
10.1371/journal.pone.0033728. [PMID: 22470466] - Weng Ieong Tou, Calvin Yu-Chian Chen. Traditional Chinese medicine as dual guardians against hypertension and cancer?.
Journal of biomolecular structure & dynamics.
2012; 30(3):299-317. doi:
10.1080/07391102.2012.680030. [PMID: 22694277] - R Neil Dalton, Raj Chetty, Mary Stuart, Renee B Iacona, Alan Swaisland. Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.
Anticancer research.
2010 Jul; 30(7):2935-42. doi:
NULL. [PMID: 20683035] - Rosemary A Hannon, Glen Clack, Martin Rimmer, Alan Swaisland, J Andrew Lockton, Richard D Finkelman, Richard Eastell. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2010 Mar; 25(3):463-71. doi:
10.1359/jbmr.090830. [PMID: 19775203]